BIO-RAD LABORATORIES, INC.
Close on Oct 19, 2026
- Market cap
- $9.46B
- P/E (TTM)
- 42.8
- Dividend yield
- –
Earnings
Next report expected Oct 28, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | During market hours | $651.00M | $13.85 | $2.62 |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | During market hours | $592.10M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 12, 2026 | During market hours | $693.20M | $26.65 | $2.51 |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 29, 2025 | During market hours | $653.00M | $-12.70 | $2.26 |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 31, 2025 | During market hours | $651.60M | $11.67 | $2.61 |
| Q1 FY2025 Ended Mar 31, 2025 | May 1, 2025 | During market hours | $585.40M | $2.29 | $2.54 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 13, 2025 | During market hours | $667.50M | $-25.57 | $2.90 |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 30, 2024 | During market hours | $649.70M | $23.34 | $2.01 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | During market hours | $638.50M | $-76.26 | $3.11 |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 15, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Aug 4, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| operating marginnon-GAAP | full-year 2026 | 10% to 12% | Maintained |
| currency-neutral revenuenon-GAAP | full-year 2026 | -3% to 0.5% growth | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Bio-Rad Laboratories filed with the SEC
Bio-Rad Reports Second -Quarter 2026 Financial Results
Results of operations · Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
Supplemental Earnings Results Presentation August 4, 2026 Second Quarter 2026 Financial Results
Results of operations · Exit or restructuring costs · Regulation FD disclosure · EX-99.2 to Form 8-K
Bio-Rad Reports First -Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Supplemental Earnings Results Presentation April 30, 2026 First Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Supplemental Earnings Results Presentation February 12, 2026 Fourth-Quarter and Full-Year 2025 Results
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Bio-Rad Reports Third -Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
October 29, 2025 Third Quarter 2025 Financial Results Bio-Rad Laboratories, Inc.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Bio-Rad Laboratories, Inc. Co-Founder and Director Emeritus Alice Schwartz Passes Away
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio-Rad Laboratories, Inc. NYSE: BIO and BIO.B August 26, 2025 Droplet Digital PCR – Powering the Future
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio-Rad Reports Second -Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations
Executive or director change · Other events · EX-99.1 to Form 8-K
Bio-Rad Reports First -Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results
Results of operations · Exit or restructuring costs · Other events · EX-99.1 to Form 8-K
B io-Rad Offers to Acquire Digital PCR Developer Stilla Technologies
Results of operations · Exit or restructuring costs · Other events · EX-99.2 to Form 8-K
Bio-Rad Reports Third-Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Bio-Rad Reports Second-Quarter 2024 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Bio-Rad Reports First-Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Bio-Rad Announces Life Science Group Management Changes
Executive or director change · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Bio-Rad Reports Third-Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Bio-Rad Reports Second-Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Bio-Rad Announces New Share Repurchase Program
Other events · EX-99.1 to Form 8-K
Bio-Rad Reports First-Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Bio-Rad Reports Fourth-Quarter and Full-Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio-Rad Reports Third-Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Bio-Rad Reports Second-Quarter 2022 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Bio-Rad Reports First-Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Bio-Rad Announces Closing of $1.2 Billion Aggregate Senior Notes Offering
Other events · EX-99.1 to Form 8-K
F E B R U A R Y 2 5 , 2 0 2 2 Bio-Rad Investor Laboratories, Inc. Day 2022
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio-Rad Presents Growth Strategy and Acceleration of Financial Targets at Investor Day
Regulation FD disclosure · EX-99.2 to Form 8-K
Bio-Rad Reports Fourth-Quarter and Full-Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Bio-Rad Reports Third-Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K